Literature DB >> 2898694

Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063.

P Guinot, C Summerhayes, L Berdah, J Duchier, R J Revillaud.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2898694     DOI： 10.1016/s0140-6736(88)90055-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

Review 2.  Clinical experience with platelet-activating factor antagonists. Past, present, and near future.

Authors:  P Guinot
Journal:  Clin Rev Allergy       Date:  1994

3.  Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis.

Authors:  J L Macpherson; A Kemp; M Rogers; A I Mallet; R F Toia; B Spur; J W Earl; C N Chesterman; S A Krilis
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

4.  In vitro platelet aggregability studies: lack of evidence for platelet hyperactivity in systemic sclerosis.

Authors:  J E Price; P S Klimiuk; M I Jayson
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

Review 5.  The pathophysiological role and therapeutic implications of platelet activating factor in diseases of aging.

Authors:  C Kroegel; C Kortsik; N Kroegel; H Matthys
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

Review 6.  The role of platelet-activating factor (PAF) in experimental glomerular injury.

Authors:  A Ortiz; M Gomez-Chiarri; J L Lerma; E Gonzalez; J Egido
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.